Predictors of the variability in neuromuscular block duration following succinylcholine: A prospective, observational study

European Journal of Anaesthesiology

Volumn 32, Issue 10, 2015, Pages 687-696

  Dell Kuster, Salome ^a,c   Levano, Soledad ^a,b   Burkhart, Christoph S ^d   Lelais, Frédéric ^b   Zemp, André ^e   Schobinger, Elektra ^b   Hampl, Karl ^b   Kindler, Christoph ^e   Girard, Thierry ^a,b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Department of Biomedicine ^*  (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; CINCHOCAINE; ETOMIDATE; FLUORIDE; METOCLOPRAMIDE; PROPOFOL; SUXAMETHONIUM; THIOPENTAL; NEUROMUSCULAR DEPOLARIZING AGENT;

ADOLESCENT; ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; CARCINOMA; COHORT ANALYSIS; COMORBIDITY; COUGHING; DRUG USE; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC VARIABILITY; GESTATIONAL AGE; GROUPS BY AGE; HEALTH STATUS; HEREDITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; MUSCLE TWITCH; NEUROMUSCULAR BLOCKING; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RESPIRATORY TRACT INTUBATION; RISK FACTOR; SEX DIFFERENCE; SURGICAL PATIENT; TERTIARY CARE CENTER; ULNAR NERVE; GENETICS; MUTATION; PREDICTIVE VALUE; PROCEDURES; TIME FACTOR;

ADULT; AGED; BUTYRYLCHOLINESTERASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR DEPOLARIZING AGENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SUCCINYLCHOLINE; TIME FACTORS;

EID: 84973480420     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0000000000000308     Document Type: Article

References (46)

1. Perry JJ, Sillberg VAH, Wells GA. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2008;CD002788.
2. Broomhead RH, Marks RJ, Ayton P. Confirmation of the ability to ventilate by facemask before administration of neuromuscular blocker: a noninstrumental piece of information? Br J Anaesth 2010; 104: 313-317.
3. Amathieu R, Combes X, Abdi W, et al. An algorithm for difficult airway management, modified for modern optical devices (Airtraq laryngoscope; LMA CTrach): a 2-year prospective validation in patients for elective abdominal, gynecologic, and thyroid surgery. Anesthesiology 2011; 114:25-33.
4. Seupeul RA, Jones JH. Does succinylcholine maximize intubating conditions better than rocuronium for rapid sequence intubation? Ann Emerg Med 2010; 20:1-2.
5. Lee C. Goodbye suxamethonium!. Anaesthesia 2009; 64 (Suppl 1): 73-81.
6. Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997; 87:979-982.
7. Heier T, Feiner JR, Lin J, et al. Hemoglobin desaturation after succinylcholine-induced apnea: a study of the recovery of spontaneous ventilation in healthy volunteers. Anesthesiology 2001; 94:754-759.
8. Hayes AH, Breslin DS, Mirakhur RK, et al. Frequency of haemoglobin desaturation with the use of succinylcholine during rapid sequence induction of anaesthesia. Acta Anaesthesiol Scand 2001; 45: 746-749.
9. Kopman AF, Zhaku B, Lai KS. 'The intubating dose' of succinylcholine: the effect of decreasing doses on recovery time. Anesthesiology 2003; 99:1050-1054.
10. El-Orbany MI, Joseph NJ, Salem MR, Klowden AJ. The neuromuscular effects and tracheal intubation conditions after small doses of succinylcholine. Anesth Analg 2004; 98:1680-1685.
11. Evans FT, Gray PW, Lehmann H, Silk E. Sensitivity to succinylcholine in relation to serum-cholinesterase. Lancet 1952; 1:1229-1230.
12. Kalow W. The distribution, destruction and elimination of muscle relaxants. Anesthesiology 1959; 20:505-518.
13. Holst-Larsen H. The hydrolysis of suxamethonium in human blood. Br J Anaesth 1976; 48:887-892.
14. Vanlinthout LE, van Egmond J, de Boo T, et al. Factors affecting magnitude and time course of neuromuscular block produced by suxamethonium. Br J Anaesth 1992; 69:29-35.
15. La Du BN. Butyrylcholinesterase variants and the new methods of molecular biology. Acta Anaesthesiol Scand 1995; 39:139-141.
16. Girard T, Kindler CH. Pharmacogenetics and anaesthesiology. Curr Pharmacogenom 2004; 2:119-135.
17. Tunek A, Svensson LA. Bambuterol a carbamate ester prodrug of terbutaline, as inhibitor of cholinesterases in human blood. Drug Metab Dispos 1988; 16:759-764.
18. Kambam JR, Parris WC, Franks JJ, et al. The inhibitory effect of metoclopramide on plasma cholinesterase activity. Can J Anaesth 1988; 35:476-478.
19. Niazi A, Leonard IE, O'Kelly B. Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency. J Clin Anesth 2004; 16:40-42.
20. Leighton BL, Cheek TG, Gross JB, et al. Succinylcholine pharmacodynamics in peripartum patients. Anesthesiology 1986; 64:202-205.
21. Pantuck EJ. Plasma cholinesterase: gene and variations. Anesth Analg 1993; 77:380-386.
22. Jensen FS, Skovgaard LT, Viby-Mogensen J. Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol Scand 1995; 39:157-162.
23. Levano S, Ginz H, Siegemund M, et al. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. Anesthesiology 2005; 102:531-535.
24. Bartels CF, Jensen FS, Lockridge O, et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992; 50:1086-1103.
25. Lando G, Mosca A, Bonora R, et al. Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italianpopulation study. Pharmacogenetics 2003; 13:265-270.
26. Yen T, Nightingale BN, Burns JC, et al. Butyrylcholinesterase (BCHE) genotyping for postsuccinylcholine apnea in an Australian population. Clin Chem 2003; 49:1297-1308.
27. Babaoglu MO, Ocal T, Bayar B, et al. Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population. Eur J Clin Pharmacol 2004; 59:875-877.
28. Cerf C, Mesguish M, Gabriel I, et al. Screening patients with prolonged neuromuscular blockade after succinylcholine and mivacurium. Anesth Analg 2002; 94:461-466.
29. Viby-Mogensen J. Succinylcholine neuromuscular blockade in subjects heterozygous for abnormal plasma cholinesterase. Anesthesiology 1981; 55:231-235.
30. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
31. Levano S, Keller D, Schobinger E, et al. Rapid and accurate detection of atypical and Kalow variants in the butyrylcholinesterase gene using denaturing high performance liquid chromatography. Anesth Analg 2008; 106:147-151.
32. Rogers WH. sg17: regression standard errors in clustered samples. Stata Tech Bull 1993; 13:19-23.
33. Hintze JL, Nelson RD. Violin plots: a box plot-density trace synergism. Am Stat 1998; 52:181-184.
34. Nogueira CP, McGuire MC, Graeser C, et al. Identification of a frameshift mutation responsible for the silent phenotype of human serum cholinesterase, Gly 117 (GGT-GGAG). Am J Hum Genet 1990; 46:934-942.
35. Primo-Parmo SL, Lightstone H, La Du BN. Characterization of an unstable variant (BChE115D) of human butyrylcholinesterase. Pharmacogenetics 1997; 7:27-34.
36. Parnas ML, Procter M, Schwarz MA, et al. Concordance of butyrylcholinesterase phenotype with genotype: implications for biochemical reporting. Am J Clin Pathol 2011; 135:271-276.
37. Naguib M, Samarkandi AH, Abdullah K, et al. Succinylcholine dosage and apnea-induced hemoglobin desaturation in patients. Anesthesiology 2005; 102:35-40.
38. Davis L, Britten JJ, Morgan M. Cholinesterase. Its significance in anaesthetic practice. Anaesthesia 1997; 52:244-260.
39. El-Orbany M, Connolly LA. Rapid sequence induction and intubation: current controversy. Anesth Analg 2010; 110:1318-1325.
40. Burr R. The effect of etomidate on the activity of human pseudocholinesterase. In vivo-in vitro-enzymekinetics. Anaesthesist 1980; 29:113-119.
41. El-Orbany MI, Joseph NJ, Salem MR. Tracheal intubating conditions and apnoea time after small-dose succinylcholine are not modified by the choice of induction agent. Br J Anaesth 2005; 95:710-714.
42. Kao YJ, Turner DR. Prolongation of succinylcholine block by metoclopramide. Anesthesiology 1989; 70:905-908.
43. Flegar-Mestric Z, Surina B, Siftar Z. Biological variations of human serum butyrylcholinesterase activity in a population from Zagreb. Croatia Chem Biol Interact 1999; 119-120:193-199.
44. Randell EW, Mathews MS, Zhang H, et al. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005; 38:799-805.
45. Chestnut RJ, Healy TE, Harper NJ, Faragher EB. Suxamethonium-the relation between dose and response. Anaesthesia 1989; 44:14-18.
46. Gatke MR, Viby-Mogensen J, Ostergaard D, Bundgaard JR. Response to mivacurium in patients carrying the k variant in the butyrylcholinesterase gene. Anesthesiology 2005; 102:503-508.